# A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

> **NCT07007793** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 250 (estimated)

## Conditions studied

- Primary Hyperaldosteronism

## Interventions

- **DRUG:** Baxdrostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07007793
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2028-02-18
- **Final completion:** 2028-02-18
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007793, "A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07007793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*